Clinical trials: Obesity or Overweight
Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes
- Trial name
- NCT07399678
- Testing
- ALV-100
- Where
- 3 sites in United States
- Volunteers
- 180 people
- Sponsor
- Alveus Therapeutics, Inc.
Overweight, Obesity
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with…
- Trial name
- NCT07589608
- Testing
- Macupatide, Eloralintide
- Where
- 40 sites in United States
- Volunteers
- 400 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
A Study of ZT002 Injection in Participants With Overweight or Obesity
This study will comprise a randomized, double-blind, placebo-controlled, multiple-ascending-dose, safety, tolerability, and pharmacokinetics study of ZT002 in participants with Overweight or Obesity.
- Trial name
- NCT06371326
- Testing
- ZT002 Injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Healthy Participants
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 After Repeat Dose Administration in Participants Who Are Overweight or Obese
A study in healthy male and female participants of non-childbearing and childbearing potential who have overweight or obesity
- Trial name
- NCT06132841
- Testing
- AZD6234
- Where
- 3 sites in United States, Japan
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight, Obesity
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake.
- Trial name
- NCT06267092
- Testing
- No treatment given, Cagrilintide and Semaglutide
- Where
- Germany
- Volunteers
- 164 people
- Sponsor
- Novo Nordisk A/S
Hypertension
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
- Trial name
- VICTOR-HTN (NCT07360275)
- Testing
- VCT220 Tablet
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Vincentage Pharma Co., Ltd
Obesity, Weight Loss
Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients
The primary objective of this study is to assess, over a period of 12 months, the effect on weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in overweight/obese patients after an initial…
- Trial name
- MODERATO (NCT00678483)
- Testing
- rimonabant (SR141716)
- Where
- 5 sites in Croatia, Finland and 3 more
- Volunteers
- 331 people
- Sponsor
- Sanofi
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Trial name
- ATTAIN-CN (NCT07790861)
- Testing
- Orforglipron
- Where
- 13 sites in China
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
Osteoarthritis, Overweight or Obesity
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have…
- Trial name
- ENLIGHTEN-4 (NCT07353931)
- Testing
- Eloralintide
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Healthy
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, and pharmacokinetics of ZT003 following subcutaneous administration in healthy adult…
- Trial name
- NCT07184502
- Testing
- ZT003 - Part1 (Single ascending dose ), ZT003 - Part 2(Multiple ascending dose )
- Where
- 2 sites in Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Beijing QL Biopharmaceutical Co.,Ltd
Overweight or Obese
A Study to Evaluate MWN109 Injection in Healthy Subjects
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
- Trial name
- NCT06859853
- Testing
- Subcutaneous single and mutiple dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity With Diabetes, Overweight With Diabetes
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: Percent change in body weight Change in hemoglobin A1c (HbA1c)
- Trial name
- KaiNETIC-2 (NCT07284901)
- Testing
- Ribupatide
- Where
- 173 sites in United States, Argentina and 9 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Overweight or Obesity
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.
- Trial name
- NCT06396429
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 567 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity and Overweight, Moderately Obese
EXploratory Study on Postprandial Energy Metabolism
This exploratory, double-blinded clinical trial on 66 randomized adults aged 50 to 70 years with moderate overweight or obesity but considered metabolically healthy will consist of comparing metabolic and microbiota parameters…
- Trial name
- EXPEM (NCT06786052)
- Testing
- Probiotic
- Where
- France
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Obesity
The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity
This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo.
- Trial name
- NCT03364335
- Testing
- Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg
- Where
- 15 sites in United States
- Volunteers
- 267 people
- Sponsor
- NuSirt Biopharma
Obesity, Overweight
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing…
- Trial name
- NCT07752979
- Testing
- ABBV-295
- Where
- 64 sites in United States, Puerto Rico
- Volunteers
- 360 people
- Sponsor
- AbbVie
Overweight , Obesity
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants…
- Trial name
- NCT07791524
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd